depymed_logo.png
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
19 mars 2024 10h59 HE | DepYmed, Inc.
FARMINGDALE, N.Y., March 19, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
depymed_logo.png
DepYmed to Meet with Investors at the BIO CEO and Investor Conference
21 févr. 2024 09h35 HE | DepYmed, Inc.
FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
depymed_logo.png
DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
07 févr. 2024 09h45 HE | DepYmed, Inc.
FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
depymed_logo.png
DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
03 oct. 2023 09h45 HE | DepYmed, Inc.
FARMINGDALE, N.Y., Oct. 03, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
depymed_logo.png
DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023
27 sept. 2023 09h45 HE | DepYmed, Inc.
FARMINGDALE, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
depymed_logo.png
DepYmed to Meet with Investors at the LSX World Congress USA in Boston on September 13-14, 2023
08 sept. 2023 09h45 HE | DepYmed, Inc.
FARMINGDALE, N.Y., Sept. 08, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
depymed_logo.png
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
15 juin 2023 09h00 HE | DepYmed, Inc.
FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
depymed_logo.png
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
31 mai 2023 09h30 HE | DepYmed, Inc.
FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
depymed_logo.png
DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
16 nov. 2022 09h35 HE | DepYmed, Inc.
FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
depymed_logo.png
DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
23 mai 2022 09h45 HE | DepYmed, Inc.
FARMINGDALE, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...